Involvement of chronic inflammation via monocyte chemoattractant protein‐1 in uraemic cardiomyopathy: a human biopsy study

Abstract Aims Patients undergoing dialysis, even those without coronary artery disease or valvular abnormalities, sometimes present with reduced heart function, which resembles dilated cardiomyopathy (DCM). This condition is known as uraemic cardiomyopathy (UCM). The mechanisms of UCM development ar...

Full description

Bibliographic Details
Main Authors: Tomoya Nakano, Kenji Onoue, Ayako Seno, Satomi Ishihara, Yasuki Nakada, Hitoshi Nakagawa, Tomoya Ueda, Taku Nishida, Tsunenari Soeda, Makoto Watanabe, Rika Kawakami, Kinta Hatakeyama, Yasuhiro Sakaguchi, Chiho Ohbayashi, Yoshihiko Saito
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:ESC Heart Failure
Subjects:
Online Access:https://doi.org/10.1002/ehf2.13423
id doaj-728ac370107d4e6ebcc294215d6aca27
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Tomoya Nakano
Kenji Onoue
Ayako Seno
Satomi Ishihara
Yasuki Nakada
Hitoshi Nakagawa
Tomoya Ueda
Taku Nishida
Tsunenari Soeda
Makoto Watanabe
Rika Kawakami
Kinta Hatakeyama
Yasuhiro Sakaguchi
Chiho Ohbayashi
Yoshihiko Saito
spellingShingle Tomoya Nakano
Kenji Onoue
Ayako Seno
Satomi Ishihara
Yasuki Nakada
Hitoshi Nakagawa
Tomoya Ueda
Taku Nishida
Tsunenari Soeda
Makoto Watanabe
Rika Kawakami
Kinta Hatakeyama
Yasuhiro Sakaguchi
Chiho Ohbayashi
Yoshihiko Saito
Involvement of chronic inflammation via monocyte chemoattractant protein‐1 in uraemic cardiomyopathy: a human biopsy study
ESC Heart Failure
Human heart tissue
Immunohistochemistry
Monocyte chemoattractant protein‐1
Placental growth factor
Uraemic cardiomyopathy
author_facet Tomoya Nakano
Kenji Onoue
Ayako Seno
Satomi Ishihara
Yasuki Nakada
Hitoshi Nakagawa
Tomoya Ueda
Taku Nishida
Tsunenari Soeda
Makoto Watanabe
Rika Kawakami
Kinta Hatakeyama
Yasuhiro Sakaguchi
Chiho Ohbayashi
Yoshihiko Saito
author_sort Tomoya Nakano
title Involvement of chronic inflammation via monocyte chemoattractant protein‐1 in uraemic cardiomyopathy: a human biopsy study
title_short Involvement of chronic inflammation via monocyte chemoattractant protein‐1 in uraemic cardiomyopathy: a human biopsy study
title_full Involvement of chronic inflammation via monocyte chemoattractant protein‐1 in uraemic cardiomyopathy: a human biopsy study
title_fullStr Involvement of chronic inflammation via monocyte chemoattractant protein‐1 in uraemic cardiomyopathy: a human biopsy study
title_full_unstemmed Involvement of chronic inflammation via monocyte chemoattractant protein‐1 in uraemic cardiomyopathy: a human biopsy study
title_sort involvement of chronic inflammation via monocyte chemoattractant protein‐1 in uraemic cardiomyopathy: a human biopsy study
publisher Wiley
series ESC Heart Failure
issn 2055-5822
publishDate 2021-08-01
description Abstract Aims Patients undergoing dialysis, even those without coronary artery disease or valvular abnormalities, sometimes present with reduced heart function, which resembles dilated cardiomyopathy (DCM). This condition is known as uraemic cardiomyopathy (UCM). The mechanisms of UCM development are not fully understood. Previous studies demonstrated that the balance between placental growth factor (PlGF) and fms‐like tyrosine kinase‐1 (Flt‐1) is correlated with renal function, and PlGF/Flt‐1 signalling is involved in the development of cardiovascular diseases in patients with chronic kidney disease. This study was conducted to evaluate the pathogenesis of UCM and clarify the differences in the mechanisms of UCM and DCM by using human endomyocardial biopsy and blood samples. Methods and results The clinical and pathological features of 30 patients on dialysis with reduced cardiac function [left ventricular ejection fraction (LVEF) ≤50%] (UCM group; mean age: 58.5 ± 9.4 years and LVEF: 39.1 ± 7.2%), 196 DCM patients (DCM group; mean age: 62.7 ± 14.0 years and LVEF: 33.5 ± 8.8%) as controls with reduced cardiac function (LVEF ≤ 45%), and 21 patients as controls with normal cardiac function (control group; mean age: 56.2 ± 19.3 years and LVEF: 67.5 ± 6.7%) were analysed. The percentage of the interstitial fibrosis area in the UCM group was greater than that in the DCM group (P = 0.045). In UCM patients, the percentage of the interstitial fibrosis area was positively correlated with the duration of renal replacement therapy (P < 0.001). The number of infiltrated CD68‐positive macrophages in the myocardium and expression of monocyte chemoattractant protein‐1 (MCP‐1) in cardiomyocytes were significantly greater in the UCM group than in the other groups (P < 0.001, respectively). Furthermore, while the serum level of soluble form of Flt‐1, an endogenous inhibitor of PlGF, in the UCM group was lower compared with that in the DCM group (P < 0.001), the serum levels of PlGF and PlGF/soluble form of Flt‐1 ratio and plasma level of MCP‐1 in the UCM group were higher than those in the DCM group (P < 0.001, respectively). Conclusions These results suggest that activated PlGF/Flt‐1 signalling and subsequent macrophage‐mediated chronic non‐infectious inflammation via MCP‐1 in the myocardium are involved in the pathogenesis of UCM.
topic Human heart tissue
Immunohistochemistry
Monocyte chemoattractant protein‐1
Placental growth factor
Uraemic cardiomyopathy
url https://doi.org/10.1002/ehf2.13423
work_keys_str_mv AT tomoyanakano involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT kenjionoue involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT ayakoseno involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT satomiishihara involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT yasukinakada involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT hitoshinakagawa involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT tomoyaueda involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT takunishida involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT tsunenarisoeda involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT makotowatanabe involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT rikakawakami involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT kintahatakeyama involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT yasuhirosakaguchi involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT chihoohbayashi involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
AT yoshihikosaito involvementofchronicinflammationviamonocytechemoattractantprotein1inuraemiccardiomyopathyahumanbiopsystudy
_version_ 1721265377236746240
spelling doaj-728ac370107d4e6ebcc294215d6aca272021-07-28T18:55:36ZengWileyESC Heart Failure2055-58222021-08-01843156316710.1002/ehf2.13423Involvement of chronic inflammation via monocyte chemoattractant protein‐1 in uraemic cardiomyopathy: a human biopsy studyTomoya Nakano0Kenji Onoue1Ayako Seno2Satomi Ishihara3Yasuki Nakada4Hitoshi Nakagawa5Tomoya Ueda6Taku Nishida7Tsunenari Soeda8Makoto Watanabe9Rika Kawakami10Kinta Hatakeyama11Yasuhiro Sakaguchi12Chiho Ohbayashi13Yoshihiko Saito14Department of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Pathology National Cerebral and Cardiovascular Center Suita Osaka JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanDepartment of Diagnostic Pathology Nara Medical University Kashihara Nara JapanDepartment of Cardiovascular Medicine Nara Medical University Kashihara Nara JapanAbstract Aims Patients undergoing dialysis, even those without coronary artery disease or valvular abnormalities, sometimes present with reduced heart function, which resembles dilated cardiomyopathy (DCM). This condition is known as uraemic cardiomyopathy (UCM). The mechanisms of UCM development are not fully understood. Previous studies demonstrated that the balance between placental growth factor (PlGF) and fms‐like tyrosine kinase‐1 (Flt‐1) is correlated with renal function, and PlGF/Flt‐1 signalling is involved in the development of cardiovascular diseases in patients with chronic kidney disease. This study was conducted to evaluate the pathogenesis of UCM and clarify the differences in the mechanisms of UCM and DCM by using human endomyocardial biopsy and blood samples. Methods and results The clinical and pathological features of 30 patients on dialysis with reduced cardiac function [left ventricular ejection fraction (LVEF) ≤50%] (UCM group; mean age: 58.5 ± 9.4 years and LVEF: 39.1 ± 7.2%), 196 DCM patients (DCM group; mean age: 62.7 ± 14.0 years and LVEF: 33.5 ± 8.8%) as controls with reduced cardiac function (LVEF ≤ 45%), and 21 patients as controls with normal cardiac function (control group; mean age: 56.2 ± 19.3 years and LVEF: 67.5 ± 6.7%) were analysed. The percentage of the interstitial fibrosis area in the UCM group was greater than that in the DCM group (P = 0.045). In UCM patients, the percentage of the interstitial fibrosis area was positively correlated with the duration of renal replacement therapy (P < 0.001). The number of infiltrated CD68‐positive macrophages in the myocardium and expression of monocyte chemoattractant protein‐1 (MCP‐1) in cardiomyocytes were significantly greater in the UCM group than in the other groups (P < 0.001, respectively). Furthermore, while the serum level of soluble form of Flt‐1, an endogenous inhibitor of PlGF, in the UCM group was lower compared with that in the DCM group (P < 0.001), the serum levels of PlGF and PlGF/soluble form of Flt‐1 ratio and plasma level of MCP‐1 in the UCM group were higher than those in the DCM group (P < 0.001, respectively). Conclusions These results suggest that activated PlGF/Flt‐1 signalling and subsequent macrophage‐mediated chronic non‐infectious inflammation via MCP‐1 in the myocardium are involved in the pathogenesis of UCM.https://doi.org/10.1002/ehf2.13423Human heart tissueImmunohistochemistryMonocyte chemoattractant protein‐1Placental growth factorUraemic cardiomyopathy